Company Overview

About Us

- Belgian biotechnology company.
- Advanced therapies for **Liver repair and organ regeneration.**
- In **Phase IIb** for an **alternative to liver transplantation, life saving indication**

Mission

Clinical development to market approval of signaling cell technologies in life saving indications

Vision

Cell Signaling Technology for Liver Repair & Organ Regeneration
Repair the native liver

Technology: Signaling Cell Platform - HepaStem®

MSCs: Medicinal Signaling Cells. MOA supported by own data and extensive literature on signaling properties

Allogeneic technology

Liver derived: **immune safety**, no immunogenicity

Prone to **gene editing** and or **transfection** → Specific target developments

Development of large pipeline of second-generation products

Well established **immunomodulatory activity**

Basal secretome enhanced by target tissue inflammation: HGF, TGFβ, PGE2, IDO, IL6. Mitochondria exchange

Homing **towards inflamed tissues and liver** after peripheral vein infusion. Anti inflammatory, anti fibrotic and regenerative innate properties

Cargo shipment and tissue delivery of active proteins and gene products. **Adaptative secretome** to local inflammation

Current Positionning

Organ

LIVER

The liver is the master organ of the body Failure of the liver causes failure of all vital organs

Diseases area

Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis, Acute Decompensation of Cirrhosis, NASH

First target

Acute on Chronic Liver Failure (ACLF)

Multiorgan failure complicating underlying chronic Liver disease

Therapeutic Solution

HepaStem® is an allogeneic Advanced Therapy derived from the liver

Simple intravenous infusion, homing to the liver, in situ immuno-modulatory and antifibrotic properties

ACLF market

Life saving indication

Highly unmet need **Alternative to liver transplantation** 96,000 patients affected/year (EU ,US, Cn, Jpn)

Production

Fully-Formed Supply Chain, Production & Platform



Product Pipeline

Developing alternatives to liver transplantation for end-stage liver diseases



Regulatory & Market Access

- Life threatening diseases, Life saving therapies
- Orphan and large indications, meeting unmet needs
- **First marketing authorization planned in 2027***
- Positive feedback on Reimbursement from EMA
- Planned orphan & RMAT designations, Priority Review

* Possibility of conditional approval Q1 2025

Unique Opportunity

Team & Track record

Etienne Sokal, M.D., Ph.D.
CEO/CMO Cellaïon Founder

Houssam Zazgad, PharmD, MBA
COO

Mustapha Najimi, Ph.D.
CSO

Bruno De Keersmaeker
Head of Finance

- Team with long standing biotech experience
- Large network of Key opinion Leaders and hepatologists.
- Focus on market authorization, acceleretad approval

Clinical

- Phase IIB ongoing
- >100 patients treated in previous and current trial
- Encouraging preliminary efficacy results in phase IIA
- Recruiting phase IIB study
- Conditional approval sought for 2025

IP

14 different patent families

Protected till >2040

More than 200 patents & patents applications on a global basis

Potential Market

Uniquely positioned in competitive landscape



Indication – Country	# Patients
ACLF – EU4+UK, US, JP, China	96,000
AAH – EU4+UK, US, JP, China	100,000
ADC – EU4+UK, US, JP, China	300,000

Investment opportunity

- Acquisition of full IP & assets of an advanced therpay platform targeting inflammation
- Very **attractive pre money value**
- Ongoing Serie A aiming to reach CSR of phase IIB.
- Financing round still open.
- Open to Partnership to develop new indications/licensing deal.

Get In Touch: ir@cellaion.com